187 results on '"Möhn, Nora"'
Search Results
2. Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset
3. The relevance of NMDA receptor antibody-specific index for diagnosis and prognosis in patients with anti-NMDA receptor encephalitis
4. Influence of hormones in multiple sclerosis: focus on the most important hormones
5. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
6. IgG4-related hypertrophic pachymeningitis with tumor-like intracranial and intracerebral lesions
7. Characteristics of hospital admission during checkpoint-inhibition therapy.
8. Innovative therapeutic concepts of progressive multifocal leukoencephalopathy
9. Neurological management and work-up of neurotoxicity associated with CAR T cell therapy
10. Neuroimmunologie von COVID‑19
11. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time
12. Editorial: Autoimmune complications of modern cancer therapies
13. Combined treatment with allogeneic Epstein–Barr- and human polyomavirus 1 specific T-cells in progressive multifocal leukoencephalopathy and EBV infection: a case report
14. 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
15. Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation
16. Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis
17. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
18. Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy
19. Progressive multifokale Leukenzephalopathie: Diagnostik und Therapieoptionen
20. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
21. Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
22. Acute progressive neuropathy–myositis–myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma
23. Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
24. Diagnose und Therapie der Multiplen Sklerose
25. Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications
26. Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor‐associated neurotoxicity.
27. The Influence of the Ventricular-Lumbar Gradient on Cerebrospinal Fluid Analysis in Serial Samples
28. Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway
29. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic
30. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease
31. Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome
32. Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy
33. Checkpoint inhibitor–induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin’s lymphoma
34. Rapid depletion of CD20+B and T cells following ofatumumab therapy onset
35. Additional file 1 of Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
36. Additional file 3 of Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
37. Effekte synthetischer Retinoid-Rezeptor-Liganden auf IL-17 produzierende γδ T-Zellen in der experimentellen Gallengangatresie
38. Additional file 2 of Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
39. Additional file 4 of Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
40. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
41. PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy
42. The Influence of Renal Function Impairment on Kappa Free Light Chains in Cerebrospinal Fluid
43. Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
44. Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy
45. Targeted metabolomic profiling of cerebrospinal fluid from patients with progressive multifocal leukoencephalopathy
46. 18F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
47. Cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
48. Results of cerebrospinal fluid analysis in 108 patients with progressive multifocal leukoencephalopathy
49. Synthetic retinoid AM80 inhibits IL‐17 production of gamma delta T cells and ameliorates biliary atresia in mice
50. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.